Efeitos da tafluprosta e da brinzolamida sobre a pressão intraocular e o diâmetro pupilar de cães saudáveis

• Ano de defesa: 2016
• Autor(a) principal: Dower, Nathalie Moro Bassil
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Mato Grosso; Brasil; Faculdade de Agronomia, Medicina Veterinária e Zootecnia (FAMEVZ); UFMT CUC - Cuiabá; Programa de Pós-Graduação em Ciências Veterinárias
• Palavras-chave em Português: Análogos das prostaglandinas; Inibidores da anidrase carbônica; Pressão intraocular; Cão; Miose; CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA; Prostaglandina analogues; Carbonic anhydrase inhibitors; Ocular hypertension; Miosis
• Link de acesso: http://ri.ufmt.br/handle/1/1158

This study aimed to evaluate the effects of topical administration of 0.0015% tafluprost and 1% brinzolamide on intraocular pressure (IOP) and pupil diameter (PD) in healthy dogs. Two experiments were carried out after a washout period of 10 days. Eleven dogs were treated with 1 drop of tafluprosta at 8:30 a.m. and 8:30 p.m., and brinzolamide at 8:30 a.m., 14:30 and 20.30 p.m. for 4 days. IOP and PD were measured at 8 and 11 a.m.; 2, 5, and 8 p.m for two days (baseline), 4 days of treatment, and 1 of post-treatment. Following 4 days, tafluprosta and brinzolamide were able to reduce IOP by 2 and 1.42 mmHg, respectively, compared to baseline. Comparisons between drugs showed a reduction of 0.62 mm Hg at the end of 4 days of treatment period (P > 0.05). At the end of this period, the average IOP of eyes treated with brinzolamide reduced only 0.90 mmHg, in comparision to the control eyes (P < 0,05 at 3rd and 4rd days); while tafluprosta reduced IOP by 3.6 mmHg (P < 0.001). Comparisons between baseline and treated eyes, showed reductions of PD by 0.34 (brinzolamide) 2.55 mm (tafluprosta). However, at the end of this period, comparisons with the control eyes showed that the average PD of the brinzolamide treated eyes decreased only 0.18 mm vs. 3.25 mm seen in tafluprost treated eyes. It can be concluded that for 4 days of treatment with 0.0015% tafluprosta and 1% brinzolamide were able to decrease significantly the IOP and the OS and can be indicated for the treatment of glaucoma and ocular hipertension. Although slighter values of IOP were observed in eyes treated with tafluprost, statistical significance were not seen when both drugs were compared. The decrease in PD induced by brinzolamide may not be clinically relevant, suggesting that the drug is not recommended to induce miosis in the dog.